MAC pricing

MAC pricing (Maximum Allowable Cost) is the pharmacy benefit manager's reimbursement ceiling for generic drugs, set on proprietary lists the PBM publishes and updates at its discretion. MAC values typically sit independent of wholesale acquisition cost and can be reset without notice, producing the largest source of reimbursement volatility for independent pharmacies. State MAC transparency laws in over 30 states require disclosure of the MAC list, a timely update mechanism, and an appeal right where reimbursement falls below acquisition cost.

How MAC pricing works

Every PBM maintains one or more MAC lists covering generic drugs the PBM has decided to price uniformly across its network. The reimbursement formula at the point of sale is the lesser of the MAC value, the pharmacy's usual and customary (U&C) charge, or the contract floor. The PBM controls the MAC list entirely, including which generics appear on it, the dollar value for each, and the update cadence. A generic with a stable WAC can move on the MAC list weekly. A drug in shortage can sit on the MAC list at a value below every wholesaler's price.

State MAC transparency laws (Arkansas, Texas, Tennessee, North Dakota, and over 30 others) require the PBM to disclose the MAC list to network pharmacies, update it within a set number of days when WAC moves, and provide a MAC appeal mechanism. The appeal mechanics, the response deadlines, and the remedy structure vary by state. The federal Rutledge v. PCMA (2020) decision confirmed that ERISA does not preempt state MAC laws, which made the state-law track meaningful for the first time.

When MAC pricing applies

MAC pricing applies to every generic drug claim a pharmacy submits to a PBM contract that incorporates MAC reimbursement, which is essentially every Medicare Part D, Medicaid managed care, and commercial PBM contract. Brand-name drugs are reimbursed on an AWP-minus formula instead. Specialty and limited-distribution drugs may follow a different reimbursement structure governed by the manufacturer's network agreement.

The pharmacy's exposure under MAC pricing

The structural exposure is below-cost reimbursement on individual claims. When the MAC value falls below the pharmacy's acquisition cost, the pharmacy dispenses at a loss and the only recovery mechanism is a MAC appeal. The compound exposure is volume: a pharmacy filling 200 generic claims a day at $2 below cost on average loses $400 per day, $146,000 per year, often without any visibility into the cause until the MAC report runs. The defense framework focuses on the state MAC transparency law track, the appeal mechanics in the provider manual, and the contractual reconciliation rights where the PBM has guaranteed an effective rate across the generic book.

Related terms

• Spread pricing The PBM practice of charging plans more than it reimburses pharmacies and keeping the difference, often tied to MAC list manipulation.
• DIR fees Performance-based Medicare Part D fees collected after the point of sale, separate from but interacting with MAC reimbursement.
• Effective rate guarantee The contractual mechanism some PBMs use to true up reimbursement across the generic book.
• Provider manual The PBM document that sets the MAC appeal mechanics and update cadence.

See also

• Practice area
  PBM Audit Defense

  The full PBM audit defense framework, including reimbursement disputes that escalate into audit findings.

• Practice area
  Recoupment Defense

  Defense framework for when MAC-related disputes produce post-payment recoupment demands.